Investors in AVEO Pharmaceuticals Inc saw new options become available this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new March 16th contracts and identified the following put contract of particular interest.

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA ® (tivozanib), a potent, selective, long half-life inhibitor of all three vascular endothelial growth...

Investors in AVEO Pharmaceuticals Inc saw new options become available this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVEO options chain for the new February 16th contracts and identified the following call contract of particular interest.

Investors in AVEO Pharmaceuticals Inc saw new options begin trading this week, for the July 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: Jefferies 2017 London Healthcare Conference...

AVEO Oncology (NASDAQ:AVEO) today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held...

AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA ® (tivozanib), has opted into the Phase 1/2 TiNivo study.

AVEO Oncology (NASDAQ:AVEO) today announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA ® (tivozanib) for the treatment of adult patients with...

AVEO Oncology (NASDAQ: AVEO) today announced that the European Commission (EC) has approved FOTIVDA ® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus...

AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for...